Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02504008




Registration number
NCT02504008
Ethics application status
Date submitted
20/07/2015
Date registered
21/07/2015
Date last updated
23/03/2018

Titles & IDs
Public title
CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1
Scientific title
CREATE-1 Study: CRPS Treatment Evaluation 1 Study. A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Oral Zoledronate) Administered Orally to Subjects With Complex Regional Pain Syndrome Type I (CRPS-I)
Secondary ID [1] 0 0
AXS02-301
Universal Trial Number (UTN)
Trial acronym
CREATE-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Complex Regional Pain Syndrome 0 0
Reflex Sympathetic Dystrophy 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - AXS-02 (oral zoledronate)
Treatment: Drugs - Placebo

Experimental: AXS-02 (oral zoledronate) - Administered orally in the morning on Days 1, 8, 15, 22, 29, and 36

Placebo comparator: Placebo - Administered orally in the morning on Day 1, 8, 15, 22, 29, and 36


Treatment: Drugs: AXS-02 (oral zoledronate)
Once weekly for 6 weeks

Treatment: Drugs: Placebo
Once weekly for 6 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in patient reported pain intensity
Timepoint [1] 0 0
Baseline to Week 12
Secondary outcome [1] 0 0
Change in Brief Pain Inventory (BPI) Pain Score
Timepoint [1] 0 0
Baseline to Week 12
Secondary outcome [2] 0 0
Patients' Global Impression of Change (PGI-C)
Timepoint [2] 0 0
Baseline to Week 12
Secondary outcome [3] 0 0
Clinicians' Global Impression of Change (CGI-C)
Timepoint [3] 0 0
Baseline to Week 12
Secondary outcome [4] 0 0
Change in EuroQOL 5-dimensions questionnaire (EQ-5D)
Timepoint [4] 0 0
Baseline to Week 12
Secondary outcome [5] 0 0
Change in Short-Form McGill Pain Questionnaire (SF-MPQ-2)
Timepoint [5] 0 0
Baseline to Week 12
Secondary outcome [6] 0 0
Change in bone turnover markers
Timepoint [6] 0 0
Baseline to Week 52

Eligibility
Key inclusion criteria
Key

* Male or female of at least 18 years of age
* Recently confirmed diagnosis of CRPS-1 (Budapest criteria)
* Average pain intensity score of = 5 (based on an 11-point scale [0 - 10])
* Willing and able to provide written informed consent

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Received chronic opioid therapy within 4 weeks
* Received a sympathetic nerve block within 3 weeks
* Active litigation or a pending workers' compensation decision
* Any other clinically significant medical or pain condition (eg, Parkinson's disease, cognitive impairment, or fibromyalgia) or clinical laboratory abnormality that would in the investigator's judgment interfere with the subject's ability to participate in the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
UNKNOWN
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/01/2019
Actual
Sample size
Target
190
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
- Broadmeadow
Recruitment hospital [2] 0 0
- Hurstville
Recruitment hospital [3] 0 0
- Noosa Heads
Recruitment hospital [4] 0 0
- Welland
Recruitment hospital [5] 0 0
- Clayton
Recruitment hospital [6] 0 0
- Nedlands
Recruitment postcode(s) [1] 0 0
- Broadmeadow
Recruitment postcode(s) [2] 0 0
- Hurstville
Recruitment postcode(s) [3] 0 0
- Noosa Heads
Recruitment postcode(s) [4] 0 0
- Welland
Recruitment postcode(s) [5] 0 0
- Clayton
Recruitment postcode(s) [6] 0 0
- Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
New Mexico
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Oklahoma
Country [14] 0 0
United States of America
State/province [14] 0 0
Oregon
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington
Country [17] 0 0
United States of America
State/province [17] 0 0
Wisconsin
Country [18] 0 0
Canada
State/province [18] 0 0
Quebec
Country [19] 0 0
United Kingdom
State/province [19] 0 0
Cheshire
Country [20] 0 0
United Kingdom
State/province [20] 0 0
County Durham
Country [21] 0 0
United Kingdom
State/province [21] 0 0
London
Country [22] 0 0
United Kingdom
State/province [22] 0 0
Merseyside
Country [23] 0 0
United Kingdom
State/province [23] 0 0
Norfolk
Country [24] 0 0
United Kingdom
State/province [24] 0 0
Tyne And Wear
Country [25] 0 0
United Kingdom
State/province [25] 0 0
Glasgow

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Axsome Therapeutics, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT02504008